Market Cap 531.26M
Revenue (ttm) 167.50M
Net Income (ttm) 52.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 31.18%
Debt to Equity Ratio 0.00
Volume 59,511
Avg Vol 141,296
Day's Range N/A - N/A
Shares Out 43.80M
Stochastic %K 64%
Beta N/A
Analysts Strong Sell
Price Target $25.00

Company Profile

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 850 5070
Address:
171 Oyster Point Blvd, Suite 300, South San Francisco, United States
Latest News on MAZE
Biotech firm Maze Therapeutics raises $140 million in US IPO

Jan 30, 2025, 7:45 PM EST - 5 months ago

Biotech firm Maze Therapeutics raises $140 million in US IPO


Maze Therapeutics targets up to $728 mln valuation in US IPO

Jan 27, 2025, 6:31 AM EST - 5 months ago

Maze Therapeutics targets up to $728 mln valuation in US IPO


Maze Therapeutics Seeks IPO For Trials Ramp-Up

Jan 13, 2025, 12:07 PM EST - 6 months ago

Maze Therapeutics Seeks IPO For Trials Ramp-Up


Maze Therapeutics IPO Registration Document (S-1)

Jan 7, 2025, 4:16 PM EST - 6 months ago

Maze Therapeutics IPO Registration Document (S-1)